5-bromopentanal dimethyl acetal | 78643-42-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-bromopentanal dimethyl acetal
• 英文别名: 5-bromo-1,1-dimethoxypentane
• CAS: 78643-42-2
• 化学式: C₇H₁₅BrO₂
• 分子量: 211.099
• InChiKey: GDVDQWWINLDHSX-UHFFFAOYSA-N

物化性质

• 沸点：
  204.9±30.0 °C(Predicted)
• 密度：
  1.239±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromopentanal dimethyl acetal 在 palladium on activated charcoal 硫酸 、 三氧化硫吡啶 、 sodium cyanoborohydride 、 potassium carbonate 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.92h， 生成 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-(furan-3-ylmethyl)aminopiperidine
  参考文献：
  名称：

  3- [3-（Piperidin-1-yl）propyl]吲哚作为高选择性h5-HT（1D）受体激动剂。

  摘要：

  几种5-HT（1D / 1B）受体激动剂目前正作为偏头痛的治疗方法进入市场。本文介绍了选择性的h5-HT（1D）受体激动剂作为潜在的偏头痛药物的发展，它可能产生较少的副作用。合成了一系列3- [3-（哌啶-1-基）丙基]吲哚，该化合物导致鉴定出80（L-772,405），这是一种具有170的高亲和力h5-HT（1D）受体全激动剂对h5-HT（1D）受体的选择性是h5-HT（1B）受体的两倍。L-772,405在一系列其他5-羟色胺和非5-羟色胺受体上也表现出非常好的选择性，并且在大鼠皮下给药后具有出色的生物利用度。因此，它构成了描述偏头痛中h5-HT（1D）受体作用的有价值的工具。

  DOI：

  10.1021/jm9910021
• 作为产物：
  描述：

  5-溴戊酸 在 amberlyst-15 、 硼烷四氢呋喃络合物 、 pyridinium chlorochromate 作用下， 以 甲醇 为溶剂， 生成 5-bromopentanal dimethyl acetal
  参考文献：
  名称：

  使用2-sily1-1,3-dithians的碳环化

  摘要：

  能够通过直接或迈克尔加成到羰基单元上而能够进行碳环化的二噻吩基阴离子可以由2-三甲基甲硅烷基-1,3-二噻烷生成。

  DOI：

  10.1039/c39810000306

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• Effects of Phosphorus Substituents on Reactions of α-Alkoxyphosphonium Salts with Nucleophiles
  作者：Akihiro Goto、Kazuki Otake、Ozora Kubo、Yoshinari Sawama、Tomohiro Maegawa、Hiromichi Fujioka

  DOI：10.1002/chem.201200480

  日期：2012.9.3

  The effects of phosphorus substituents on the reactivity of α‐alkoxyphosphonium salts with nucleophiles has been explored. Reactions of α‐alkoxyphosphonium salts, prepared from various acetals and tris(o‐tolyl)phosphine, with a variety of nucleophiles proceeded efficiently. These processes represent the first examples of high‐yielding nucleophilic substitution reactions of α‐alkoxyphosphonium salts

  研究了磷取代基对α-烷氧基salts盐与亲核试剂反应性的影响。由各种缩醛和三（邻甲苯基）膦制备的α-烷氧基phosph盐与各种亲核试剂的反应有效进行。这些过程代表了α-烷氧基phosph盐高亲核取代反应的第一个例子。这些盐的反应性分别取决于空间和电子因素之间的平衡，分别由锥角θ和CO拉伸频率ν（分别为空间和电子参数）表示。此外，由Ph 3衍生的α-烷氧基phosph盐的新反应观察到带有格氏试剂的P在O 2的存在下发生，以高收率得到醇。为此过程提出了一种自由基机理，该机理已获得同位素标记和自由基抑制实验的支持。
• Substituted indolylpropyl-piperazine derivatives as 5-HT.sub.1D .alpha.
  申请人：Merck Sharp & Dohme Limited

  公开号：US05981529A1

  公开（公告）日：1999-11-09

  A class of 1-[3-(1H-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, on one or other of the ethylene carbon atoms of the phenethyl moiety by halogen, trifluoromethyl, alkyl, hydroxyalkyl or alkoxyalkyl, and optionally on the phenyl ring of the phenethyl moiety by halogen, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

  一类1-[3-(1H-吲哚-3-基)丙基]-4-(2-苯乙基)哌嗪衍生物，通过在吲哚核的5位被一个五元杂环芳基取代，在苯乙基的乙烯碳原子上通过卤素、三氟甲基、烷基、羟基烷基或烷氧基取代，以及在苯乙基的苯环上通过卤素、三氟甲基、烷氧基或氧杂环丙酮基，并可选择性地通过一个或两个进一步的取代基，它们是5-HT.sub.1-样受体的选择性激动剂，是人类5-HT.sub.1D .alpha.受体亚型的有效激动剂，同时相对于5-HT.sub.1D .beta.亚型具有至少10倍的选择性亲和力；因此，在治疗和/或预防临床病症，特别是偏头痛及相关疾病方面，对于需要5-HT.sub.1D受体亚型选择性激动剂的情况，它们比非亚型选择性的5-HT.sub.1D受体激动剂引起的副作用更少，尤其是不良心血管事件。
• Indoline and azaindoline derivatives as 5-HT.sub.1D alpha receptor
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05919783A1

  公开（公告）日：1999-07-06

  Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole, and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1-4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1-6 carbon atoms; T represents nitrogen or CH; R.sup.1 represents aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, either of which groups may be optionally substituted; and R.sup.2 represents hydrogen or C.sub.1-6 alkyl are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##

  式(I)的化合物，或其盐或前药，其中Z代表从呋喃、噻吩、吡咯、噁唑、噻唑、异噁唑、异噻唑、咪唑、吡唑、噁二唑、噻二唑、三唑和四唑中选择的可选择性取代的五元杂芳环；E代表化学键或含有1-4个碳原子的直链或支链烷基链；Q代表含有1-6个碳原子的直链或支链烷基链；T代表氮或CH；R.sup.1代表芳基(C.sub.1-6)烷基或杂芳基(C.sub.1-6)烷基，其中任一组可能可选择性取代；R.sup.2代表氢或C.sub.1-6烷基是5-HT.sub.1-样受体的选择性激动剂，是人类5-HT.sub.1D.alpha.受体亚型的有效激动剂，同时相对于5-HT.sub.1D.beta.亚型具有至少10倍的选择性亲和力；因此，在治疗和/或预防临床病症方面具有用途，特别是偏头痛及相关疾病，需要5-HT.sub.1D受体亚型选择性激动剂，同时引起的副作用较少，尤其是不良心血管事件，相对于与非亚型选择性5-HT.sub.1D受体激动剂相关的副作用。
• Piperazine, piperidine and tetrahydropyridine derivative of
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05807857A1

  公开（公告）日：1998-09-15

  Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R.sup.2 ; V represents oxygen, sulphur or N--R.sup.3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH.dbd.C--; R.sup.1 represents C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, any of which groups may be optionally substituted; and R.sup.2 and R.sup.3 independently represent hydrogen or C.sub.1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

  式(I)的化合物，或其盐或前药，其中Z代表从呋喃、噻吩、吡咯、噁唑、噻唑、异噁唑、异噻唑、咪唑、吡唑、噁二唑、噻二唑、三唑和四唑中选择的可选择性取代的五元杂芳环；E代表化学键或含有1至4个碳原子的直链或支链烷基链；Q代表含有1至6个碳原子的直链或支链烷基链，在任何位置可选择性地被羟基取代；T代表氮或CH；U代表氮或C--R.sup.2；V代表氧、硫或N--R.sup.3；--F--G--代表--CH2--N--，--CH2--CH--或--CH.dbd.C--；R.sup.1代表C.sub.3-6烯基、C.sub.3-6炔基、芳基(C.sub.1-6)烷基或杂芳基(C.sub.1-6)烷基，其中任何一个基团可选择性地被取代；而R.sup.2和R.sup.3独立地代表氢或C.sub.1-6烷基，是5-HT1D受体的选择性激动剂，是人类5-HT1Dα受体亚型的有效激动剂，同时相对于5-HT1Dbeta亚型，具有至少10倍的选择性亲和力；因此，在治疗和/或预防临床病症方面特别是偏头痛及相关疾病方面，对于需要5-HT1D受体亚型选择性激动剂的情况，比非亚型选择性5-HT1D受体激动剂引起的副作用更少，尤其是不良心血管事件。